$55.93+1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 28, 2026
Company outlook: revenue of about $290M for Fiscal year 2026 — up 28.8% on a year earlier
Just reported
From Axogen, Inc.'s results release of October 28, 2026; its quarterly report has since been filed.
Actual
$75.8M
+26% y/y
+8.8% q/q
Guided
—
No guide given
Actual
$0.04
+300% y/y
Guided
—
No guide given
Actual
$955K
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $75.8M | $60.1M | +26.22% |
| Profit | $2.3M | $708K | +229.66% |
| Profit per share | $0.04 | $0.01 | +300.00% |
| Free Cash Flow | $15.1M | $1.7M | +789.25% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Axogen, Inc. has no earnings call transcript available.
“We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s strategic plan priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s product portfolio includes Avance ® (acellular nerve allograft-arwx), Avance ® Nerve Graft, Axoguard Nerve Connector ® , Axoguard Nerve Protector ® , Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap ® , Avive+ Soft Tissue Matrix ® , and NerveTape ® .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Axogen, Inc.’s Item 2.02 8-K filed October 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
-50% y/y
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.